全部照片(1)
About This Item
經驗公式(希爾表示法):
C16H14N2O4
CAS號碼:
分子量::
298.29
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
推薦產品
品質等級
化驗
≥98% (HPLC)
形狀
powder
顏色
yellow
溶解度
DMSO: ≥10 mg/mL
儲存溫度
2-8°C
SMILES 字串
COc1ccc(cc1)-n2c(C)c([N+]([O-])=O)c3ccc(O)cc23
InChI
1S/C16H14N2O4/c1-10-16(18(20)21)14-8-5-12(19)9-15(14)17(10)11-3-6-13(22-2)7-4-11/h3-9,19H,1-2H3
InChI 密鑰
VVZNWYXIOADGSW-UHFFFAOYSA-N
一般說明
ID-8 是双特异性酪氨酸磷酸化调节激酶 1A (DYRK1A) 的抑制剂。
生化/生理作用
ID-8 在体外维持小鼠胚胎干细胞 (ESC) 的自我更新和多潜能性。以稳定的速度刺激增殖(在添加 10 μg/ml 的无血清培养基中观察到)M 为期 30 天)。
在体外维持小鼠胚胎干细胞 (ESC) 的自我更新和多能性。
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
Stefan Hindel et al.
PloS one, 10(6), e0128060-e0128060 (2015-06-11)
The purpose of our study was to validate perfusion quantification in a low-perfused tissue by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with shared k-space sampling using a blood pool contrast agent. Perfusion measurements were performed in a total of seven
Yusuke Higuchi et al.
Current molecular pharmacology, 9(3), 272-279 (2015-05-27)
Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and
A High-Throughput Screen Identifies DYRK1A inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell Proliferation
Monteiro M B, et al.
Journal of the American Society of Nephrology, ASN-2018040392 (2018)
Jin Zhou et al.
Annals of translational medicine, 8(20), 1295-1295 (2020-11-20)
In Chinese herbal medicine, Tanshinone IIA (Tan-IIA) is one of the main compounds extracted from Salvia miltiorrhiza Bunge. Tan-IIA has been demonstrated to inhibit the growth of various tumors. However, the detailed molecular and cellular mechanisms of the antitumor effect
Amy A Lo et al.
Molecular cancer therapeutics, 20(4), 716-725 (2021-02-05)
Ovarian cancer is a diverse class of tumors with very few effective treatment options and suboptimal response rates in early clinical studies using immunotherapies. Here we describe LY6/PLAUR domain containing 1 (LYPD1) as a novel target for therapeutic antibodies for
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務